ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has a beta value of 2.00 and has seen 9.45 million shares traded in the recent trading session. The company, currently valued at $381.50M, closed the recent trade at $2.13 per share which meant it gained $0.48 on the day or 29.09% during that session. The ZIOP stock price is -179.34% off its 52-week high price of $5.95 and 40.85% above the 52-week low of $1.26. The 3-month trading volume is 1.96 million shares.
The consensus among analysts is that ZIOPHARM Oncology Inc. (ZIOP) is an Overweight stock at the moment, with a recommendation rating of 2.60. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 4 out of 7 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.12.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) trade information
Sporting 29.09% in the green today, the stock has traded in the red over the last five days, with the highest price hit on Friday, 09/03/21 when the ZIOP stock price touched $2.13 or saw a fall of -0.47%. Year-to-date, ZIOPHARM Oncology Inc. shares have moved -34.52%, while the 5-day performance has seen it change -6.25%. Over the past 30 days, the shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) have changed -28.57%.
Wall Street analysts have a consensus price target for the stock at $4.33, which means that the shares’ value could jump 50.81% from the levels at last check today. The projected low price target is $3.00 while the price target rests at a high of $7.50. In that case, then, we find that the latest price level in today’s session is -252.11% off the targeted high while a plunge would see the stock gain -40.85% from the levels at last check today.
ZIOPHARM Oncology Inc. (ZIOP) estimates and forecasts
Figures show that ZIOPHARM Oncology Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -59.46% over the past 6 months, with this year growth rate of -21.05%, compared to 7.50% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are -33.30% and -20.00% for the next quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 16.80% over the past 5 years.
ZIOPHARM Oncology Inc. is expected to release its next earnings report between November 03 and November 08 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s Major holders
Insiders own 9.98% of the company shares, while shares held by institutions stand at 57.47% with a share float percentage of 63.85%. Investors are also buoyed by the number of investors in a company, with ZIOPHARM Oncology Inc. having a total of 218 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 16.39 million shares worth more than $43.28 million. As of Jun 29, 2021, Blackrock Inc. held 7.60% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 15.78 million shares as of Jun 29, 2021. The firm’s total holdings are worth over $41.65 million and represent 7.32% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. As of Jun 29, 2021, the former fund manager holds about 3.08% shares in the company for having 6.63 million shares of worth $17.51 million while later fund manager owns 5.81 million shares of worth $15.35 million as of Jun 29, 2021, which makes it owner of about 2.70% of company’s outstanding stock.